Genfit (NASDAQ:GNFT) Shares Down 3.5%

Genfit S.A. (NASDAQ:GNFT – Get Rating) was down 3.5% during trading on Monday . The stock traded as low as $3.70 and last traded at $3.78. Approximately 8,129 shares changed hands during trading, an increase of 4% from the average daily volume of 7,847 shares. The stock had previously closed at $3.91.

Wall Street Analyst Weigh In

Separately, Bank of America reduced their price objective on shares of Genfit from $5.00 to $4.00 in a research report on Friday, March 17th.

Get Genfit alerts:

Genfit Stock Performance

The company’s 50-day simple moving average is $4.28 and its 200 day simple moving average is $4.06.

Institutional Investors Weigh In On Genfit

Several institutional investors have recently added to or reduced their stakes in GNFT. Ritholtz Wealth Management purchased a new stake in Genfit during the third quarter worth $108,000. Envestnet Asset Management Inc. acquired a new position in shares of Genfit in the third quarter valued at approximately $70,000. Citadel Advisors LLC increased its stake in Genfit by 181.8% during the 3rd quarter. Citadel Advisors LLC now owns 35,319 shares of the company’s stock worth $129,000 after buying an additional 22,786 shares during the period. BNP Paribas Arbitrage SNC raised its stake in shares of Genfit by 1,992.8% in the third quarter. BNP Paribas Arbitrage SNC now owns 11,845 shares of the company’s stock valued at $43,000 after acquiring an additional 11,279 shares in the last quarter. Finally, Optiver Holding B.V. grew its stake in shares of Genfit by 33.5% during the fourth quarter. Optiver Holding B.V. now owns 23,678 shares of the company’s stock worth $103,000 after purchasing an additional 5,945 shares in the last quarter. Institutional investors and hedge funds own 4.54% of the company’s stock.

About Genfit

(Get Rating)

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments.

See Also

• Get a free copy of the StockNews.com research report on Genfit (GNFT)
• This Is Why Penny Stock GreenPower Motor Company Is A Win
• Comcast Sum of All Parts is Producing a Cumulative Effect
• The Greenbrier Companies: All Aboard For High-Yield In 2023
• Coty Stock is on the Comeback Trail
• Is Halliburton Stock a Value or a Value Trap?

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.